Patrick Han
About Patrick Han
Patrick Han is an Associate Research Scientist at Yale University, focusing on the mechanisms of cross-presentation in physiologic Dendritic Cells. He has a background in Chemical Engineering and Immunobiology, with experience in various research and academic roles.
Work at Yale University
Patrick Han has been employed at Yale University since 2019 as an Associate Research Scientist in the Department of Dermatology and Immunobiology. His research primarily focuses on the mechanisms of cross-presentation in physiologic Dendritic Cells (phDCs). He is jointly affiliated with Edelson and Cresswell Labs, contributing to projects that investigate the role of 8-Methoxypsoralen (8MOP) in inducing immunogenic cell death (ICD) and the development of cellular immunotherapy using phDCs.
Education and Expertise
Patrick Han studied at Columbia University, where he earned a Bachelor of Science (B.S.) in Chemical Engineering from 2007 to 2011. He continued his education at Yale University, pursuing a Doctor of Philosophy (Ph.D.) in Chemical & Environmental Engineering, Biomedical Engineering, and Immunobiology since 2012. His academic background provides a strong foundation for his research in immunobiology and dendritic cell mechanisms.
Previous Work Experience
Prior to his current role at Yale University, Patrick Han held several positions that contributed to his expertise. He worked as an IT Specialist in the Department of Chemistry at Columbia University for four months in 2011. He also served as a Graduate Student Researcher at the US Environmental Protection Agency (EPA) in 2018 for 11 months. Additionally, he gained experience as a Research Assistant in the Department of Earth and Environmental Engineering at Columbia University in 2012.
Research Contributions
Patrick Han's research contributions include investigating the mechanisms of cross-presentation in physiologic Dendritic Cells (phDCs) and the role of 8-Methoxypsoralen (8MOP) in immunogenic cell death (ICD). He is involved in developing cellular immunotherapy strategies utilizing phDCs, aiming to enhance therapeutic approaches in immunology.